Novo Nordisk ’s oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

The U.S. Food and Drug Administration on Thursday announced a new program to speed up construction and review of drug ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

By taking 36 mg once per day - without food and water restrictions - participants lost an average of 12.4 percent of their body weight - about 27.3 pounds (12.4 kilograms). This was over the span of ...

Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

However, the late-stage study results fell short of Novo Nordisk ’s injectable Wegovy, which delivered 14.9 per cent weight loss over 68 weeks in a 2021 trial. Lilly shares plummeted 14 per cent in ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

US stocks were mixed Thursday morning as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...